[Efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma].

作者：Y X Xia, H Zhang, F Zhang, X C Li, Dawei Rong, Weibing Tang, Hui Cao, Junyan Zhao, Pengfei Wang, Liyong Pu, Xiaoyun Qian, Fenggan Cheng, K Wang, Lianbao Kong, C Y Zhang, Dongzheng Li, Jing Song, A H Yao, Xiaofeng Wu, Chaoying Wu, Xuehao Wang · 发表于：PubMed · 年份：2022 · DOI：10.3760/cma.j.cn112139-20220408-00150 · 被引用次数：2 · 研究领域：Ferroptosis and cancer prognosis、Hepatocellular Carcinoma Treatment and Prognosis、Bladder and Urothelial Cancer Treatments

Immune checkpoint inhibitors combined with anti-angiogenic targeted drugs as a neoadjuvant therapy for resectable hepatocellular carcinoma can reduce the 1-year recurrence rate and improve the 1-year survival rate,especially for those with solitary tumor. Limited by the sample size of the neoadjuvant group,the safety of immune combined targeted therapy before surgery cannot be observed more comprehensively,and further studies will be explored.